The results of a new study show donor corneas not suitable for transplants may serve as a more effective alternative to traditional tissue for patients needing tissue to cover a glaucoma shunt, ...

The multi‐site VITA trial, a prospective pilot study designed to assess the safety and effectiveness of Avisi Technologies' investigational VisiPlate® device, enrolled and treated 15 subjects (mean ...

ALEXANDRIA, MN - January 24, 2026 - PRESSADVANTAGE - Individuals living with or at risk for glaucoma in the region can ...

Please provide your email address to receive an email when new articles are posted on . Sulcus placement is more technically difficult but preserves endothelial cells. Consider factors such as eye ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. NASHVILLE, Tenn. — Patients with glaucoma who underwent ...

REDWOOD CITY, Calif., Nov. 3, 2025 /PRNewswire/ -- Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, presented positive twelve-month clinical ...

The use of aqueous shunts for the management of refractory glaucoma is increasing compared with trabeculectomy. The number of shunts being placed increased 184% from 1995 to 2004. Commonly used ...

Company’s first-of-its-kind titratable glaucoma therapy system aims to optimize intraocular pressure (IOP) reduction for patients with moderate to severe glaucoma Results demonstrate significant IOP ...

For example, currently, CMS considers ICD-9-CM series 365.10-365.15, open-angle glaucoma as medically necessary to perform Category III code 0192T. Operative documentation must support all conditions ...

Glaucoma can be treated with eye drops, pills, laser surgery, traditional incisional surgery, newer minimally invasive surgical alternatives or a combination of these methods. The goal of any ...

Two recent studies by a UB researcher could help increase safety and minimize expense for patients undergoing glaucoma surgery. The studies were conducted over several years by Asher Weiner, clinical ...

REDWOOD CITY, Calif., April 2, 2025 /PRNewswire/ -- Avisi Technologies, a clinical-stage ophthalmic device company, today announced encouraging six‐month interim results from the VITA trial evaluating ...